Highlights Altimmune, Inc.

Equities

ALT

US02155H2004

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
8.01 ^USD	-10.00%		+10.94%	-28.80%

09/05	Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024
09/05	Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000	09/05	MT
Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
North American Morning Briefing : More Earnings -2-	30/04	DJ
Altimmune Shares Slip Wednesday, After Reporting a Wider Q4 Net Loss and Dropping Prospective Treatment for Hepatitis B	27/03	MT
Altimmune, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/03	CI
Earnings Flash (ALT) ALTIMMUNE Reports Q4 Revenue $37,000	27/03	MT
North American Morning Briefing : Inflation Data -2-	12/03	DJ
Drugmakers deepen efforts to tap into booming market for obesity drugs	27/02	RE
Zealand shares surge on liver drug data from Boehringer pact	26/02	RE
Altimmune shares slide after Kerrisdale Capital takes short position	13/02	RE
Weight loss drug windfall attracts pharma companies	11/01	RE
Drugmakers plot way into obesity market with deals and development	11/01	RE
Roche enters obesity drugs race with $2.7 bln Carmot deal	04/12	RE
Roche enters obesity drugs race with $2.7 bln Carmot deal	04/12	RE
Altimmune, Inc. Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide	01/12	CI
Earnings Flash (ALT) ALTIMMUNE Reports Q3 Revenue $362,000	07/11	MT
Altimmune, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11	CI
Altimmune Gets FDA Fast Track Label for Pemvidutide to Treat Non-Alcoholic Steatohepatitis	26/23/26	MT
Altimmune, Inc. Grants Fast Track Designation by FDA for Pemvidutide for the Treatment of Non Alcoholic Steatohepatitis	26/23/26	CI
Altimmune, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Altimmune, Inc.

Equities

ALT

US02155H2004

Highlights

Filters